Phenotypes associated with this allele

• Allele Symbol: Tg(Prox1-EGFP)KY221Gsat
• Allele Name: transgene insertion KY221, GENSAT Project at Rockefeller University
• Allele ID: MGI:4847348
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Cyp26b1^tm1Hmd/Cyp26b1^tm1Hmd Tg(Prox1-EGFP)KY221Gsat/0	involves: 129S1/Sv * 129X1/SvJ * FVB/NTac	MGI:5824825
tg2	Tg(Prox1-EGFP)KY221Gsat/0	involves: FVB/NTac	MGI:5824823

Genotype
MGI:5824825

cn1

• Allelic Composition: Cyp26b1^tm1Hmd/Cyp26b1^tm1Hmd; Tg(Prox1-EGFP)KY221Gsat/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * FVB/NTac

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

abnormal lymphatic vessel morphology ( J:206581 )

• mice exhibit hyperplastic, blood-filled deep and superficial lymphatics due to defects in lympho-venous valve patterning compared with wild-type mice

• jugular lymph sacs are enlarged compared to in wild-type mice

abnormal lymphatic vessel endothelial cell morphology ( J:206581 )

• expanded and ectopic distribution of PROX1+ and LYVE1 lymphatic endothelial cell progenitor (LEC) cells to the ventral and medial aspects of the cardinal vein at E11.5

• mice exhibit an increase in the pool of venous LEC progenitors due to increased proliferation compared with wild-type mice

cardiovascular system

cardiovascular system phenotype ( J:206581 )

N • overall morphology and size of veins are normal

hemorrhage ( J:206581 )

• hemorrhage in the region of the developing jugular lymph sacs at E13.5

homeostasis/metabolism

skin edema ( J:206581 )

• pronounced edema at E14.5 and E16.5

integument

skin edema ( J:206581 )

• pronounced edema at E14.5 and E16.5

Genotype
MGI:5824823

tg2

• Allelic Composition: Tg(Prox1-EGFP)KY221Gsat/0
• Genetic Background: involves: FVB/NTac

Galectin-8 markedly enhances VEGF-C-induced lymphangiogenesis in vivo in Tg(Prox1-EGFP)KY221Gsat/0 mice

immune system

abnormal lymphangiogenesis ( J:235778 )

• in corneal micropocket assays, corneas implanted with both VEGF-C and galectin-8 pellets show enhanced VEGF-C induced lymphangiogenesis relative to corneas implanted with either VEGF-C or galectin-8 pellets alone, as calculated by the lymphatic vessel area on day 7 post-surgery

• after suture placement or silver nitrate cauterization to induce corneal inflammation, treatment with TDG (a pan inhibitor of galectins) or Gal-8N (a dominant negative inhibitor of galectin-8) significantly suppresses both suture- and cautery-induced inflammatory lymphangiogenesis, as quantified by the lymphatic vessel area at the end of the treatment period

abnormal lymphatic vessel endothelial cell morphology ( J:235778 )

• in corneal micropocket assays, corneas implanted with either VEGF-C or galectin-8 pellets exhibit >35% of proliferative lymphatic endothelial cells (Prox1+ Ki67+ LECs) in lymphangiogenic areas, whereas corneas implanted with control pellets show <4% of Prox1+ Ki67+ LECs on day 7 post-surgery